Trial Profile
A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2021
Price :
$35
*
At a glance
- Drugs Galidesivir (Primary)
- Indications Ebola virus infections; Marburg virus disease; Yellow fever; Zika virus infection
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioCryst Pharmaceuticals
- 24 Jan 2020 Planned End Date changed from 1 May 2019 to 1 Mar 2020.
- 11 Jan 2019 New trial record
- 08 Jan 2019 Planned End Date changed to 1 May 2019.